Preliminary In Vitro Effects of CD8+ T Lymphocyte Specific for the CD20 Alternative Splicing D393-CD20 Peptide Expressed on Burkitt Lymphoma Cells

Document Type : Research Articles


1 Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

2 Department of Infectious, Parasitic and Immune-Mediated Diseases, National Institute of Health, Viale Regina Elena 299, 00161 Rome, Italy.

3 Department of Stem Cells and Developmental Biology, Cell Science Research Centre, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.

4 National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.


The effective discovery of clinically relevant tumor antigens holds a fundamental role for the development of
new diagnostic tools and anticancer immunotherapies. D393-CD20 mRNA is absent from normal resting B cells but
present in various malignant or transformed B cells. CD8+T lymphocytes play a central role in immunity to cancer.
In this study, we want use from T CD8+ against D393-CD20 for effect in RAMOS cell line. After isolation and
expanding of specific TCD8 + Lymphocyte against D393-CD20 antigen, for examining the effect of specialized T
lymphocyte clone of D393-CD20 antigen on RAMOS cell line, we co-cultured them together, and the rate of apoptosis
were examined by flow cytometry and cytotoxicity techniques by using MTT technique. We observed that specialized
TCD8+ lymphocyte of D393-CD20 antigen can induce apoptosis in malignant B-lymphocytes, and this antigen can
be a proper target for immunotherapy.


Main Subjects